IMPLICATION OF HUMAN FC RECEPTORS POLYMORPHISM IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA

Authors

  • Iuliana Magdalena STÂRCEA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • V.E. ROȘU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Anca Viorica IVANOV “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ingrith Crenguța MIRON “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Roxana POPESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • L.M. ANTOCI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C.G. CIOBANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Elena-Lia SPOIALA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • V.V. LUPU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Solange Tamara ROȘU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Mirabela-Smaranda ALECSA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Carmen Daniela RUSU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ancușa LUPU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cristina GAVRILOVICI “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Keywords:

FCGR POLYMORPHISM, IMMUNE THROMBOCYTOPENIC PURPURA, CHILDREN, PLATELETS

Abstract

Immune thrombocytopenic purpura (ITP) is the most frequent form of autoimmune disease in childhood, characterized by thrombocytopenia (platelet count <150·109/L) with otherwise normal cell lineages. One of the main mechanisms is the platelet destruction by phagocytic cells, covered by human Fc receptors (FCGR). The FCR family involves 3 classes of receptors: FCGR1A, 1B, and 1C; FCGR2A, 2B, and 2C; FCGR3A and 3B, all present on chromosome 1q23-24. The response to ITP treatment may be influenced by the polymorphism of the FCGR3A gene, which contributes to different levels of destruction of antibody - bound platelets. Material and methods: We report the results of FCGR2/3 polymorphic genotypes in 16 children with ITP admitted at the “Sf. Maria” Emergency Children’s Hospital, Iasi, Romania, treated with corticosteroids, intravenous immunoglobulin (IVIg) or both, or conservative treatment, with a minimum of one year follow up. Results: We identified 9/16 patients with FCGR2C ORF haplotypes, 8 in heterozygous state and one in homozygous state, and 15/16 patients with FCGR2A-His166 variant. While it was previously reported that classical FCGR2C-ORF and 2B.4 variants correlate with the transient form of ITP and a good response to IVIg, in our sample it was present only in 3 patients, who had limited course of disease and a good response to IVIg. 5 patients were heterozygotes for FCGR2C-p.Gln62Trp, all of them developing an acute form, a good response to IVIg and no relapses. Furthermore, it has been demonstrated an association between FCGR genotypes characterized by increased immunoglobulin binding activity (FCGR3A allele V158 and FGCGR3B allele NA1) and chronic children ITP. In our study, only 2/16 patients express NA1 in homozygous state, one of them developing persistent ITP, while the other responded well to the treatment and did not relapse. Conclusions: Genetic influences contribute to the pathogenesis of ITP in children and response to IVIg. We evaluated the genetic risk factors in the FCGR2/3 locus that are associated with predisposition to limited course and a favorable response to IVIg in ITP in children. However, confirmation in a larger prospectively recruited cohort of children with ITP is needed.

Author Biographies

  • Iuliana Magdalena STÂRCEA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • V.E. ROȘU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Anca Viorica IVANOV, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Ingrith Crenguța MIRON, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Roxana POPESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • L.M. ANTOCI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • C.G. CIOBANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Elena-Lia SPOIALA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • V.V. LUPU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Solange Tamara ROȘU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Medical Specialties (II)

  • Mirabela-Smaranda ALECSA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Carmen Daniela RUSU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Surgery (II)

  • Ancușa LUPU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

  • Cristina GAVRILOVICI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Mother and Child Medicine

References

morim DM, Silveira Vda S, Scrideli CA, Queiroz RG, Tone LG. Fcgamma receptor gene polymor-phisms in childhood immune thrombocytopenic purpura. Journal of pediatric hematology/oncology 2012; 34: 349-352 / doi:10.1097/MPH.0b013e3182580908.
2. Bruin M, Bierings M, Uiterwaal C, et al. Platelet count, previous infection and FCGR2B genotype predict development of chronic disease in newly diagnosed idiopathic thrombocytopenia in childhood: results of a prospective study. Br J Haematol 2004; 127: 561-567 / doi:10.1111/j.1365-2141.2004.05235.x.
3. Arepally, G, McKenzie, S.E, Jiang, X.-M, Poncz, M, Cines, D.B. FcγRIIA H/R131 Polymorphism, Subclass-Specific IgG Anti-Heparin/Platelet Factor 4 Antibodies and Clinical Course in Patients With Heparin-Induced Thrombocytopenia and Thrombosis. Blood 1997; 89: 370-375 / doi:10.1182/blood.V89.2.370.
4. Niederer HA, Willcocks LC, Rayner TF, et al. Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet 2010; 19: 3282-3294 / doi:10.1093/ hmg/ddq216.
5. Mahaweni NM, Olieslagers TI, Rivas IO, et al. A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. Sci Rep 2018; 8: 15983 / doi:10.1038/s41598-018-34258-1.
6. Fujimoto, T.T, Inoue, M, Shimomura, T, Fujimura, K. Involvement of Fc gamma receptor polymorphism in the therapeutic response of idiopathic thrombocytopenic purpura. Br J Haematol 2001; 115: 125-130 / doi:10.1046/j.1365-2141.2001.03109.x.
7. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombo-cytopenic purpura. The Journal of Pediatrics 2002; 141: 683-688 / doi:10.1067/mpd.2002.128547.
8. Resmerita I, Cozma RS, Popescu R, et al. Genetics of Hearing Impairment in North-Eastern Romania-A Cost-Effective Improved Diagnosis and Literature Review. Genes 2020; 11 / doi:10.3390/genes11121506.
9. Nagelkerke SQ, Tacke CE, Breunis WB, et al. Nonallelic homologous recombination of the FCGR2/3 locus results in copy number variation and novel chimeric FCGR2 genes with aberrant functional expression. Genes and immunity 2015; 16: 422-429 / doi:10.1038/ gene.2015.25.
10. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993; 14: 215-221 / doi:10.1016/0167-5699(93) 90166-I.
11. Manger, K, Repp, R, Jansen, M, et al. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 2002; 61: 786-792 / doi:10.1136/ard.61.9.786.
12. Vedeler CA, Myh K.M, Nyland H. Fc receptors for immunoglobulin G-a role in the pathogenesis of Guillain-Barre syndrome and multiple sclerosis. J Neuroimmunol 2001; 118: 187-193 / doi:10.1016/s0165-5728(01)00344-7.
13. Nagelkerke SQ, Tacke CE, Breunis WB, et al. Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Front Immunol 2019; 10: 185 / doi:10.3389/fimmu.2019.00185.
14. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991; 147: 1338-1343.
15. Foster CB, Zhu S, Erichsen HC, et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 2001; 113: 596-599 / doi:10.1046/j.1365-2141.2001.02807.x.
16. Lejeune J, Piegu B, Gouilleux-Gruart V, Ohresser M, Watier H, Thibault G. FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymor-phisms in a Caucasian population. MAbs 2012; 4: 784-787 / doi:10.4161/mabs.22287.
17. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
18. Bredius RG, Fijen CA, De Haas M, et al. Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 1994; 83: 624-630.
19. Sanders LA, Feldman RG, Voorhorst-Ogink MM, et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 1995; 63: 73-81 / doi:10.1128/iai.63.1.73-81.1995.
20. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996; 97: 1348-1354 / doi:10.1172/JCI118552.
21. Li G, Gao L, Ma R, Tian W, Mingzhi L. Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis. Scand J Immunol 2019; 89: e12758 / doi:10.1111/sji.12758.
22. Carcao MD, Blanchette VS, Wakefield CD, et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 2003; 120: 135-141 / doi:10.1046/j.1365-2141. 2003. 04033.x.
23. Papagianni A, Economou M, Tragiannidis A, et al. FcgammaRIIa and FcgammaRIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome. Blood Coagul Fibrinolysis 2013; 24: 35-39 / doi:10.1097/ MBC. 0b013e328359bc3b.
24. Zakaria M, Al-Akhras A, Hassan T, et al. FcgammaRIIa and FcgammaRIIIa genes polymorphism in Egyptian children with primary immune thrombocytopenia. Hematol Transfus Cell Ther 2023; 45: 58-65 / doi:10.1016/j.htct.2021.05.007.
25. Breunis WB, van Mirre E, Bruin M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 2008; 111: 1029-1038 / doi:10.1182/blood-2007-03-079913.
26. Schmidt DE, Heitink-Polle KMJ, Laarhoven AG, et al. Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-gamma receptor polymorphisms. Blood Adv 2019; 3: 2003-2012 / doi:10.1182/ blood advances.2019000068.
27. Heitink-Polle KMJ, Uiterwaal C, Porcelijn L, et al. Intravenous immunoglobulin vs. observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood 2018; 132: 883-891 / doi:10.1182/blood-2018-02-830844.
28. Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW. Genetic Variation in Low-To-Medium-Affinity Fcgamma Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine. Front Immunol 2019; 10: 2237 / doi:10.3389/ fimmu.2019.02237.
29. Su K, Wu J, Edberg JC, McKenzie, S.E, Kimberly, R.P. Genomic organization of classical human low-affinity Fcgamma receptor genes. Genes Immun 2002, 3 Suppl 1, S51-56, doi:10.1038/sj.gene.6363879.
30. Gavrilovici C, Oprea L. Clinical ethics, Research ethics and community ethics – The moral triad of nowadays society. Revista Română de Bioeticǎ 2013; 11: 3.

Additional Files

Published

2023-06-30